-
Technology
-
Industry
-
Solutions
-
- ASSET MANAGEMENT
- CUSTOMER EXPERIENCE MANAGEMENT
- CYBER SECURITY
- DATA CENTER
- DOCUMENT MANAGEMENT
- ELECTRONIC DATA INTERCHANGE
- ENTERPRISE DATA MANAGEMENT
- ENTERPRISE RESOURCE PLANNING
- ENTERPRISE RISK MANAGEMENT
- ENTERPRISE-GRADE WEB DATA SOLUTIONS
- FACILITY MANAGEMENT
- FIELD SERVICE
- IDENTITY AND ACCESS MANAGEMENT
- INFRASTRUCTURE
- IT SERVICE MANAGEMENT
- MANAGED IT SERVICES
- PAYMENT AND CARD
- PROJECT MANAGEMENT
- SOFTWARE TESTING
- STORAGE
- VIDEO SOLUTIONS
- WORKFLOW
-
-
Platforms
-
Functions
- Leadership Perspectives
- Innovation Insights
- Research
- Magazines
- News
- CXO Awards
Ellen Reilly, CEOSware, the intelligent, data-driven GxP (Good “x” Practice) validation platform for life sciences companies, is a key driver of this shift.
After switching to Sware’s platform, the organization’s validation time dropped by up to 80 percent. This transformation didn’t come from adding headcount or extending work hours. It came from treating compliance as data instead of documents. This approach is gaining traction across the life sciences domain.
“For over 45 years, validation has been trapped in paper and documents. We built a system that treats it as data,” says Ellen Reilly, CEO.
Res_Q for Modern Compliance
At the center of Sware’s platform is Res_Q, short for Responsible Quality, which changes this long-standing status quo. The system stores validation activity as structured, linked records, replacing scattered documents with organized data. It gives teams a complete lifecycle view of their systems. Administrators and engineering leads gain visibility into how updates move through workflows. Quality and IT leaders see the full lifecycle, not isolated pieces of validation. Teams working with equipment and lab automation understand how their systems connect to the broader compliance picture.
The platform runs on AWS with enterprise-grade security, is SOC 2 compliant and uses open APIs so organizations can connect it with their existing systems seamlessly. Its AI capabilities automate routine validation tasks, reducing manual touchpoints and helping teams move through updates faster. By keeping all activity in unified records, the platform supports faster reviews and brings consistency across sites.
For over 45 years, validation has been trapped in paper and documents. We built a system that treats it as data.
This structure aligns with the FDA’s move toward computer software assurance (CSA), which promotes a risk-based approach to validation. Sware is designed to support that shift, moving away from the document-centric thinking that shaped earlier validation tools.
Sware’s rollout supports both small teams and large global groups, with some organizations getting started in two to three weeks. Larger organizations, depending on their business processes, follow a blueprint that takes 4 to 12 weeks. Teams can begin in one area and scale to their entire organization.
The company supports organizations across FDA-regulated environments, from life sciences to companies subject to laboratory, manufacturing or clinical practice requirements. Sware also works with software firms, including Salesforce Life Sciences Cloud, which uses the platform to support GxP compliance. For development teams, Sware offers the GxPNext platform, which embeds GxP controls directly into the software lifecycle and supports compliant releases.
Expanding Capabilities and Maintaining Control
Sware recently launched its mobile application, “Res_Q Mobile”, while new AI capabilities with expanded mobile functionality are moving ahead as part of its larger AI roadmap. Medical device and animal health companies are also adopting the platform, reflecting shared regulatory challenges across FDA-regulated sectors. These sectors face similar FDA requirements as pharmaceutical manufacturers and represent natural extensions of the company’s core expertise.
What distinguishes Sware’s approach is the insight teams gain from their validation work. The system gives heads of quality, IT and manufacturing visibility into how their processes run and where automation can support them. It turns compliance activity into something leaders can track, measure and report on with consistency—capabilities that document-based systems struggle to provide.
With Sware, compliance data delivers both speed and oversight across the GxP validation lifecycle.
AI-Enabled GxP Validation: The Capabilities Transforming Compliance in Life Sciences
For decades, life sciences GxP validation has been an exercise in document management rather than a pursuit of quality assurance. Leadership teams in the pharmaceutical and biotech sectors often find themselves tied to paper-based review cycles and manual tracking, which stall innovation. These legacy processes create a significant bottleneck as organizations try to scale in an era of rapid software updates and complex laboratory automation. The modern enterprise requires a shift from the document-centric practice to a structured data-driven model that prioritizes risk-based assessment and real-time oversight.
The evaluation of a suitable solution must center on its ability to treat compliance activity as structured linked records rather than static files. A gold-standard platform should provide a unified view across the entire system lifecycle, allowing quality and IT leaders to constantly track updates. This level of transparency is essential for maintaining audit readiness and ensuring data integrity across multiple sites and applications. Technical requirements for such a system include an open API architecture to facilitate integration with existing toolsets, along with enterprise-grade security and SOC 2 compliance to protect intellectual property.
The emergence of computer software assurance (CSA) further underscores the need for platforms that automate routine tasks while maintaining rigorous control. The best solutions now leverage generative and agentic AI to handle monitoring and flag milestones, reducing the manual touchpoints that typically lead to human error. By shifting the focus to critical thinking and high-value oversight, organizations can move away from blanket testing and focus on areas with the highest risk profiles. This transition allows global manufacturing groups to accelerate release cycles without compromising the safety and efficacy standards mandated by international regulatory bodies.
Sware stands as the right choice for organizations seeking to modernize their compliance posture. Its Res_Q platform transforms GxP validation into an intelligent data-driven process, reducing validation time by up to 80 percent for global enterprises. The platform manages complex environments across information technology and manufacturing through a single source of truth, replacing scattered documents with organized data. Meanwhile, its GxPNext platform enables the embedding of controls into development lifecycles, ensuring that releases are inherently compliant. Through its recently launched mobile application, “Res_Q Mobile,” and its advanced AI roadmap, Sware provides the speed and clarity necessary for modern life sciences leaders to maintain a state of continuous audit readiness....Read more
Company
Sware
Management
Ellen Reilly, CEO
Description
Sware delivers a data-driven GxP validation platform built for life sciences. Its Res_Q and GxPNext products replace document-heavy workflows with structured data, open APIs and generative/agentic AI. Designed for manufacturers and software vendors, the solution supports faster, traceable and scalable validation.
